HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Malignant neoplasm of pleura — Clinical Guidelines

Overview

Malignant neoplasm of the pleura, commonly known as malignant pleural mesothelioma (MPM), is a highly aggressive cancer primarily associated with asbestos exposure. It predominantly affects the pleura, the thin membrane surrounding the lungs, but can also involve adjacent structures such as the diaphragm and pericardium. MPM is characterized by rapid progression and poor prognosis, with median survival often measured in months rather than years. The incidence is higher in older adults, particularly those with a history of occupational asbestos exposure, though sporadic cases occur without clear exposure history. Early detection and comprehensive multidisciplinary management are crucial in day-to-day practice to optimize patient outcomes and manage symptoms effectively 1 2.

Pathophysiology

The pathophysiology of malignant pleural mesothelioma involves complex molecular and cellular mechanisms that lead to tumor development and progression. Asbestos fibers, once inhaled, trigger chronic inflammation and genotoxic stress in mesothelial cells lining the pleura. This exposure initiates aberrant cell signaling pathways, including activation of oncogenes like NF2 (neurofibromatosis type 2) and CDKN2A, and inactivation of tumor suppressor genes. Epigenetic modifications and dysregulation of cell cycle control further contribute to uncontrolled proliferation. Over time, these processes result in the formation of malignant mesothelioma cells that invade local tissues and can metastasize to distant organs. The interaction between asbestos fibers and mesothelial cells also promotes angiogenesis and immune evasion, facilitating tumor growth and spread 1 3.

Epidemiology

Malignant pleural mesothelioma has a global incidence rate of approximately 1-2 cases per million population annually, with significant geographic variations. In regions with high asbestos exposure, such as certain parts of Europe, North America, and some Pacific Rim countries, incidence rates are notably higher. The disease predominantly affects individuals aged 60 years and older, with a male predominance due to occupational exposure patterns. Over time, incidence trends have shown an increasing pattern in populations with historical asbestos use, though recent declines are observed in areas implementing stricter regulations. Notably, studies highlight disparities in treatment approaches and outcomes between different racial groups, with black patients less frequently undergoing cancer-directed surgery compared to white patients, despite comparable survival rates 2 4.

Clinical Presentation

Patients with malignant pleural mesothelioma typically present with nonspecific symptoms that can delay diagnosis. Common manifestations include dyspnea, chest pain, and weight loss. Persistent pleural effusions often lead to dyspnea and cough, while chest pain may be due to tumor invasion into chest wall structures or pleura. Other red-flag features include unexplained ascites, pericardial effusion, and signs of superior vena cava syndrome. Advanced disease may present with more systemic symptoms like fatigue and cachexia. Early recognition of these symptoms and prompt diagnostic evaluation are essential to initiate timely intervention 1 2.

Diagnosis

The diagnostic approach for malignant pleural mesothelioma involves a combination of imaging, cytology, and histopathology. Key steps include:

Imaging Studies: Contrast-enhanced CT scans of the chest are essential for initial evaluation, often revealing pleural thickening, nodules, or effusions. MRI can provide additional detail on tumor extent and involvement of adjacent structures 1.

Cytology: Pleural fluid analysis via thoracentesis can detect malignant cells, though sensitivity is limited.

Histopathology: Definitive diagnosis relies on biopsy samples obtained via thoracoscopy, open thoracotomy, or image-guided needle aspiration. Immunohistochemical staining for markers like calretinin, WT-1, and CK5/6 helps differentiate mesothelioma from other malignancies 1 2.

Specific Criteria and Tests:

Biopsy Confirmation: Required for diagnosis.

Imaging Criteria: Pleural thickening >1 cm, nodular pleural masses, or pleural effusion with suspicious cytology.

Histological Grading: Utilize R classification (resection status) and TNM staging system for prognostic stratification 1 20.

Differential Diagnosis:

Lung Cancer: Differentiated by location and specific histological features.

Metastatic Disease: History of primary malignancy and imaging characteristics help distinguish.

Benign Pleural Effusions: Absence of malignant cells on cytology and imaging findings 1 2.

Management

First-Line Treatment

Surgical Resection: For localized disease, extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D) may be considered. EPP involves removal of the affected lung, parietal pleura, pericardium, and diaphragm, while P/D focuses on debulking the tumor within the pleural cavity 1 6.

Adjuvant Therapy: Post-surgery, adjuvant chemotherapy (e.g., pemetrexed with cisplatin) is often recommended to target residual disease 1 2.

Second-Line and Refractory Management

Systemic Chemotherapy: For unresectable or recurrent disease, regimens like gemcitabine/cisplatin or vinorelbine/cisplatin are used 1.

Immunotherapy: Anti-PD-1/PD-L1 antibodies (e.g., pembrolizumab) have shown promise in clinical trials for selected patients 1 5.

Radiation Therapy: Palliative radiation can alleviate symptoms such as pain and dyspnea 1.

Specifics:

EPP: Indicated for early-stage disease; associated with significant morbidity.

P/D: Less invasive, suitable for selected patients; may preserve lung function.

Chemotherapy: Pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 every 3 weeks for 6 cycles 1.

Immunotherapy: Pembrolizumab 200 mg IV every 3 weeks (Evidence: Moderate) 1 5.

Contraindications:

Severe cardiopulmonary comorbidities precluding major surgery.

Active infection or significant comorbidities limiting tolerance to aggressive treatments.

Complications

Acute Complications

Postoperative Morbidity: Bleeding, respiratory failure, and infections are common post-surgery.

Hemothorax: Risk of recurrent pleural effusions requiring re-intervention.

Long-Term Complications

Recurrent Disease: Local recurrence or distant metastasis.

Symptom Management: Chronic pain, dyspnea, and cachexia require ongoing palliative care.

Management Triggers:

Persistent fever or signs of infection warrant immediate evaluation.

Symptomatic progression necessitates reassessment of treatment strategy, including palliative interventions 1 2.

Prognosis & Follow-Up

The prognosis for malignant pleural mesothelioma remains poor, with median survival typically ranging from 12 to 24 months post-diagnosis, depending on stage and treatment response. Prognostic indicators include early stage at diagnosis, epithelioid histology, and absence of lymph node or distant metastases. Regular follow-up involves:

Clinical Assessments: Every 3-6 months initially, then annually.

Imaging: CT scans every 6-12 months to monitor disease progression.

Laboratory Tests: Blood counts and tumor markers (if applicable) to assess systemic effects 1 2.

Special Populations

Elderly Patients

Considerations: Reduced tolerance to aggressive treatments; focus on palliative care and symptom management.

Management: Tailored surgical and medical interventions based on functional status and comorbidities 1.

Racial Disparities

Observation: Black patients are less likely to undergo cancer-directed surgery but have survival rates comparable to white patients.

Recommendations: Address disparities through enhanced patient education and multidisciplinary care coordination 2 4.

Key Recommendations

Multidisciplinary Approach: Engage thoracic surgeons, oncologists, radiologists, and palliative care specialists in treatment planning (Evidence: Strong) 1 2.

Early Diagnosis and Staging: Utilize advanced imaging and biopsy techniques for accurate staging (Evidence: Strong) 1.

Surgical Resection for Early-Stage Disease: Consider EPP or P/D based on patient fitness and tumor characteristics (Evidence: Moderate) 1 6.

Adjuvant Chemotherapy Post-Surgery: Standard regimen of pemetrexed with cisplatin for 6 cycles (Evidence: Strong) 1.

Consider Immunotherapy for Selected Patients: Evaluate pembrolizumab in advanced or recurrent disease (Evidence: Moderate) 1 5.

Regular Follow-Up: Schedule clinical assessments and imaging every 3-6 months initially, then annually (Evidence: Moderate) 1 2.

Address Racial Disparities: Implement strategies to ensure equitable access to cancer-directed surgery and comprehensive care (Evidence: Expert opinion) 2 4.

Palliative Care Integration: Integrate palliative care early to manage symptoms and improve quality of life (Evidence: Moderate) 1.

Monitor for Recurrence: Regular imaging and clinical evaluations to detect early recurrence (Evidence: Moderate) 1.

Patient Education: Provide detailed information on treatment options, prognosis, and support resources (Evidence: Expert opinion) 1.

References

1 Arif R, Eichhorn F, Kallenbach K, Seppelt P, Ruhparwar A, Dienemann H et al.. Resection of thoracic malignancies infiltrating cardiac structures with use of cardiopulmonary bypass. Journal of cardiothoracic surgery 2015. link 2 Taioli E, Wolf AS, Moline JM, Camacho-Rivera M, Flores RM. Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma. Disease markers 2015. link 3 Photowala F, Hatipoglu US, Garcia C. An older patient with bilateral non-traumatic haemothoraces. BMJ case reports 2012. link 4 Rosenbaum JJ, Varma S, Kirkpatrick M, Udelsman BV. Scoping Review of Operative Management of Thoracic Malignancies in Patients With Psychiatric Comorbidities. The Journal of surgical research 2025. link 5 Kamel MK, Stiles BM, Ghaly G, Rahouma M, Nasar A, Port JL et al.. Predictors of Pleural Implants in Patients With Thymic Tumors. The Annals of thoracic surgery 2016. link 6 Bölükbas S, Eberlein M, Oguzhan S, Schirren M, Sponholz S, Schirren J. Extended thymectomy including lung-sparing pleurectomy for the treatment of thymic malignancies with pleural spread. The Thoracic and cardiovascular surgeon 2015. link 7 Chang AS, Smedira NG, Chang CL, Benavides MM, Myhre U, Feng J et al.. Cardiac surgery after mediastinal radiation: extent of exposure influences outcome. The Journal of thoracic and cardiovascular surgery 2007. link 8 Vanakesa T, Goldstraw P. Antero-superior approaches in the practice of thoracic surgery. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 1999. link00102-5)

Malignant neoplasm of pleura